CAMP and COVID-19: Therefore, although the elevation of LL-37 during SARS-CoV-2 infection may be a protective mechanism of the innate immune system, the increase in LL-37 may also aggravate disease progress by inducing thrombosis, which may explain the controversy of vitamin D (inducer of LL-37 production) treatment in COVID-19 [56].